40
Participants
Start Date
June 30, 2015
Primary Completion Date
February 25, 2019
Study Completion Date
February 25, 2019
PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2
PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2
PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2
PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2
PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2
PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2
Thomas Jefferson University, Philadelphia
Virginia Piper Cancer Institute, part of Allina Health System, Minneapolis
Rush University Cancer Center, Chicago
University of Oklahoma Stephenson Cancer Center, Oklahoma City
University of Texas MD Anderson Cancer Center, Houston
Centura Health Research Center, Denver
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Rakuten Medical, Inc.
INDUSTRY